Triple-negative breast cancer: new hope for an existing drug
RI-MUHC team takes another step toward precision medicine by targeting a biomarker of CDK4/6 inhibitor efficacy in breast cancer, including triple-negative...
Prescribing personalized lifestyle interventions to improve prostate cancer treatments
David Labbé of the RI-MUHC co-leads a new project recently funded by the Marathon of Hope Cancer Centres...
$2 million dollars awarded to RI-MUHC team studying lung health
Dr. Benjamin Smith receives CIHR funding to lead research on inflammation and lung health in diverse populations
A modernized Clinical Trials Network to tackle health challenges associated with HIV and other sexually transmitted and blood-borne infections in Canada
Dr. Marina Klein will lead the network...
Researchers find a possible therapeutic target in the “genetic landscape” of aggressive and deadly pediatric brain tumours
A new study reveals that PFA ependymoma brain tumours display...
McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Novel drug could provide hope to those suffering from neuropathic pain and insomnia
Increasing clinical trial expertise at the RI-MUHC
The RI-MUHC ACT-CTU reports on the realization of its vision for 2024 to build a clinical trials community and strengthen trial capabilities at the RI-MUHC
RI-MUHC study uses AI to understand liver cancer
A new publication describes the use of ALiX, a unique AI model, to analyze data from liquid biopsy
Developing technology for fight against antimicrobial resistance
New treatment under development by researchers Karine Auclair and Andréanne Lupien could potentially treat intracellular infections without...
A clinical trial shows benefits of finding and treating undiagnosed asthma and COPD
This innovative Canadian study, published in the New England Journal of Medicine, marks a world first